TRYP — Tryp Therapeutics Income Statement
0.000.00%
Last trade - 00:00- CA$5.79m
- CA$8.73m
Annual income statement for Tryp Therapeutics, fiscal year end - August 31st, CAD millions except per share, conversion factor applied.
2020 August 31st | 2021 August 31st | 2022 August 31st | 2023 August 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | ARS | ARS | ARS |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Total Revenue | 0 | 0 | 0 | 0 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 0.423 | 8.25 | 7.49 | 4.74 |
| Operating Profit | -0.423 | -8.25 | -7.49 | -4.74 |
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -0.423 | -8.25 | -7.49 | -5.27 |
| Net Income After Taxes | -0.423 | -8.25 | -7.49 | -5.27 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -0.423 | -8.25 | -7.49 | -5.27 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -0.423 | -8.25 | -7.49 | -5.27 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -0.007 | -0.127 | -0.096 | -0.055 |
| Dividends per Share |